![Ruijin Hospital](https://trials-media.s3.amazonaws.com/orgs/ruijin-hospital.jpeg)
Zanubrutinib, Lenalidomide and Rituximab (ZR2) in Elderly Treatment-naive Patients With Diffuse...
Diffuse Large B Cell LymphomaThis is a prospective, single-center, open-label, single-arm clinical study designed to evaluate the efficacy and safety of the Zanubrutinib, Lenalidomide and Rituximab (ZR2) regimen in elderly treatment-naive patient with diffuse large B-cell lymphomas.
![Tessa Therapeutics](https://trials-media.s3.amazonaws.com/orgs/tessa-therapeutics.jpeg)
Phase 1 Study of Autologous CD30.CAR-T in Relapsed or Refractory CD30 Positive Non-Hodgkin Lymphoma...
Anaplastic Large Cell LymphomaPeripheral T Cell Lymphoma3 moreThis is a phase 1 study to evaluate safety and dose-limiting toxicity of autologous CD30.CAR-T in subjects with relapsed or refractory CD30+ Non-Hodgkin Lymphoma
![Masonic Cancer Center, University of Minnesota](https://trials-media.s3.amazonaws.com/orgs/masonic-cancer-center-university-of-minnesota.jpeg)
FT596 With Rituximab as Relapse Prevention After Autologous HSCT for NHL
NHLNon Hodgkin Lymphoma2 moreThis is a Phase I multi-center study to evaluate the safety of FT596 when given with rituximab as relapse prevention in patients who have undergone an autologous hematopoietic stem cell transplant (auto-HSCT) for diffuse large or high-grade B cell lymphoma.
![Calibr, a division of Scripps Research](https://trials-media.s3.amazonaws.com/orgs/calibr-a-division-of-scripps-research.jpeg)
CLBR001 and SWI019 in Patients With Relapsed / Refractory B-cell Malignancies
Relapsed/Refractory B-cell LymphomasDiffuse Large B Cell Lymphoma (DLBCL)10 moreCLBR001 + SWI019 is an combination investigational immunotherapy being evaluated as a potential treatment for patients diagnosed with B cell malignancies who are refractory or unresponsive to salvage therapy or who cannot be considered for or have progressed after autologous hematopoietic cell transplantation. This first-in-human study will assess the safety and tolerability of CLBR001 + SWI019 and is designed to determine the maximum tolerated dose (MTD) or optimal SWI019 dose (OSD). Patients will be administered a single infusion of CLBR001 cells followed by cycles of SWI019. The study will also assess the pharmacokinetics and pharmacodynamics of CLBR001 + SWI019.
![Fondazione Italiana Linfomi - ETS](https://trials-media.s3.amazonaws.com/orgs/fondazione-italiana-linfomi-ets.jpeg)
Copanlisib With Rituximab-Bendamustine in Patients With Relapsed-Refractory Diffuse Large B-cell...
Diffuse Large B-cell LymphomaThis is a multicentric single arm phase II trial, to investigate the efficacy (in terms of PFS) of the combination regimen rituximab-bendamustine in association with copanlisib in patients affected by relapsed/refractory DLBCL, not eligible to HDC and ASCT or relapsed after intensified regimens.
![University College, London](https://trials-media.s3.amazonaws.com/orgs/university-college-london.jpeg)
RadiothErapy priMIng for CAR-T
Diffuse Large B Cell LymphomaThe REMIT trial will investigate radiotherapy as a preferred bridging method prior to Tisagenlecleucel infusion in patients with relapsed or refractory Diffuse Large B Cell Lymphoma
![SWOG Cancer Research Network](https://trials-media.s3.amazonaws.com/orgs/swog-cancer-research-network.jpeg)
S1001 PET-Directed Therapy in Treating Patients With Limited-Stage Diffuse Large B-Cell Lymphoma...
LymphomaRATIONALE: Drugs used in chemotherapy, such as cyclophosphamide, doxorubicin hydrochloride, vincristine sulfate, and prednisone, work in different ways to stop cancer cells, either by killing the cells or by stopping them from dividing. Radiation therapy uses high-energy x-rays to kill cancer cells. Monoclonal antibodies, such as rituximab, can block cancer growth in different ways. Some block the ability of cancer cells to grow and spread. Others find cancer cells and help kill them or carry cancer-killing substances to them. Radiolabeled monoclonal antibodies, such as yttrium Y 90 ibritumomab tiuxetan, can find cancer cells and carry cancer-killing substances to them without harming normal cells. Comparing results of diagnostic procedures, such as PET scan and CT scan, done before, during, and after chemotherapy may help doctors predict a patient's response to treatment and help plan the best treatment. PURPOSE: This phase II trial studies how well PET-directed chemotherapy works in treating patients with limited-stage diffuse large B-cell lymphoma.
![Hoffmann-La Roche](https://trials-media.s3.amazonaws.com/orgs/hoffmann-la-roche.jpeg)
A Study to Evaluate the Safety and Efficacy of Polatuzumab Vedotin in Combination With Rituximab,...
Diffuse Large B-Cell LymphomaThis study is a multicenter, open-label study of polatuzumab vedotin administered by intravenous (IV) infusion in combination with rituximab, gemcitabine and oxaliplatin (R-GemOx) in participants with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). The study comprises of two stages: a safety run-in stage and a randomized controlled trial (RCT).
![Mayo Clinic](https://trials-media.s3.amazonaws.com/orgs/mayo-clinic.jpeg)
Parsaclisib With or Without Polatuzumab Vedotin Plus the Standard Drug Therapy in Patients With...
Ann Arbor Stage II Diffuse Large B-Cell LymphomaAnn Arbor Stage II Follicular Lymphoma14 moreThis phase I/Ib trial studies the side effects and best dose of parsaclisib with or without polatuzumab-vedotin (Pola) plus the standard drug therapy (rituximab, cyclophosphamide, doxorubicin hydrochloride, vincristine sulfate, and prednisone [PaR-CHOP]) and to see how well they work compared with R-CHOP alone in treating patients with newly diagnosed, high risk diffuse large B-cell lymphoma. Parsaclisib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Rituximab is a monoclonal antibody that may interfere with the ability of cancer cells to grow and spread. Polatuzumab-vedotin is a monoclonal antibody, called polatuzumab, linked to a chemotherapy drug, called vedotin. Polatuzumab is a form of targeted therapy because it attaches to specific molecules (receptors) on the surface of cancer cells, known as anti-CD79b receptors, and delivers vedotin to kill them. Drugs used in chemotherapy, such as cyclophosphamide, doxorubicin hydrochloride, and vincristine sulfate, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Anti-inflammatory drugs, such as prednisone, lower the body's immune response and are used with other drugs in the treatment of some types of cancer. It is not yet known if giving parsaclisib and R-CHOP together works better than R-CHOP alone in treating patients with high risk diffuse large B-cell lymphoma.
![Chipscreen Biosciences, Ltd.](https://trials-media.s3.amazonaws.com/orgs/chipscreen-biosciences-ltd.jpeg)
Phase III Study of Tucidinostat in Combination With R-CHOP in Patients With Newly Diagnosed Double-Expressor...
Diffuse Large B-cell LymphomaTucidinostat (formerly known as chidamide) is an oral subtype-selective histone deacetylase inhibitor. This Randomized, Double-blind, Placebo-controlled Phase 3 trail is studying the efficacy and safety of Tucidinostat, in Combination with Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Subjects With Newly Diagnosed MYC/BCL2 Double-Expressor Diffuse Large B-cell Lymphoma.